Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma

This work was supported by the National Institute for Health Research (NIHR) Biomedical Research center at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. I Chau: Advisory board fees from Eli-Lilly, BristolMeyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, AstraZeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim, Incyte and Astella; research funding from Eli-Lilly, Janssen-Cilag, Sanofi Oncology and honorarium from Eli-Lilly. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

留言 (0)

沒有登入
gif